Biohaven Ltd
BHVN10.720USD
+0.220+2.10%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.13BMarket Cap
LossP/E TTM
More Details of Biohaven Ltd Company
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Biohaven Ltd Info
Ticker SymbolBHVN
Company nameBiohaven Ltd
IPO dateSep 23, 2022
CEOCoric (Vlad)
Number of employees256
Security typeOrdinary Share
Fiscal year-endSep 23
Address215 Church Street
CityNEW HAVEN
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code06510
Phone12034040410
Websitehttps://www.biohaven.com/
Ticker SymbolBHVN
IPO dateSep 23, 2022
CEOCoric (Vlad)
Company Executives of Biohaven Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
+24.69%
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Kimberly Gentile
Ms. Kimberly Gentile
Senior Vice President of Clinical Operations
Senior Vice President of Clinical Operations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
+24.69%
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
5.11%
1919 Investment Counsel, LLC
4.98%
BlackRock Institutional Trust Company, N.A.
4.94%
Childs John W
4.91%
Suvretta Capital Management, LLC
4.24%
Other
75.83%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
5.11%
1919 Investment Counsel, LLC
4.98%
BlackRock Institutional Trust Company, N.A.
4.94%
Childs John W
4.91%
Suvretta Capital Management, LLC
4.24%
Other
75.83%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.60%
Investment Advisor/Hedge Fund
20.43%
Hedge Fund
13.94%
Individual Investor
9.18%
Research Firm
3.29%
Sovereign Wealth Fund
0.68%
Venture Capital
0.41%
Corporation
0.38%
Pension Fund
0.35%
Other
25.75%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
573
86.14M
79.56%
+56.74K
2025Q3
585
86.08M
100.43%
-2.05M
2025Q2
570
88.15M
95.46%
-3.76M
2025Q1
560
91.76M
98.48%
-8.79M
2024Q4
552
92.88M
95.24%
+5.30M
2024Q3
538
88.35M
95.17%
+3.19M
2024Q2
505
84.45M
87.45%
+8.19M
2024Q1
484
76.13M
96.08%
-2.46M
2023Q4
433
73.36M
88.24%
+6.86M
2023Q3
386
63.55M
100.60%
+1.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
5.05M
4.78%
-1.38M
-21.51%
Jun 30, 2025
1919 Investment Counsel, LLC
6.60M
6.23%
+2.50K
+0.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.44M
6.08%
+113.23K
+1.79%
Jun 30, 2025
Childs John W
6.51M
6.15%
+351.58K
+5.71%
Mar 10, 2025
Suvretta Capital Management, LLC
5.62M
5.31%
--
--
Jun 30, 2025
State Street Investment Management (US)
3.54M
3.34%
+115.81K
+3.38%
Jun 30, 2025
Coric (Vladimir)
3.18M
3%
+26.57K
+0.84%
Mar 10, 2025
The Vanguard Group, Inc.
9.23M
8.72%
+828.80K
+9.87%
Jun 30, 2025
Bellevue Asset Management AG
2.80M
2.65%
+762.00K
+37.34%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.66M
1.57%
-246.36K
-12.89%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
2.64%
Roundhill GLP-1 & Weight Loss ETF
2.18%
Simplify Health Care ETF
1.58%
Virtus LifeSci Biotech Clinical Trials ETF
0.75%
State Street SPDR S&P Biotech ETF
0.69%
Direxion Daily S&P Biotech Bull 3X Shares
0.42%
WisdomTree BioRevolution Fund
0.33%
Optimize Strategy Index ETF
0.24%
Inspire Small/Mid Cap ESG ETF
0.24%
JPMorgan Fundamental Data Science Small Core ETF
0.2%
View more
iShares Neuroscience and Healthcare ETF
Proportion2.64%
Roundhill GLP-1 & Weight Loss ETF
Proportion2.18%
Simplify Health Care ETF
Proportion1.58%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.75%
State Street SPDR S&P Biotech ETF
Proportion0.69%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.42%
WisdomTree BioRevolution Fund
Proportion0.33%
Optimize Strategy Index ETF
Proportion0.24%
Inspire Small/Mid Cap ESG ETF
Proportion0.24%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.2%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Biohaven Ltd?
The top five shareholders of Biohaven Ltd are:
Janus Henderson Investors holds 5.05M shares, accounting for 4.78% of the total shares.
1919 Investment Counsel, LLC holds 6.60M shares, accounting for 6.23% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.44M shares, accounting for 6.08% of the total shares.
Childs John W holds 6.51M shares, accounting for 6.15% of the total shares.
Suvretta Capital Management, LLC holds 5.62M shares, accounting for 5.31% of the total shares.
Janus Henderson Investors holds 5.05M shares, accounting for 4.78% of the total shares.
1919 Investment Counsel, LLC holds 6.60M shares, accounting for 6.23% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.44M shares, accounting for 6.08% of the total shares.
Childs John W holds 6.51M shares, accounting for 6.15% of the total shares.
Suvretta Capital Management, LLC holds 5.62M shares, accounting for 5.31% of the total shares.
What are the top three shareholder types of Biohaven Ltd?
The top three shareholder types of Biohaven Ltd are:
Janus Henderson Investors
1919 Investment Counsel, LLC
BlackRock Institutional Trust Company, N.A.
Janus Henderson Investors
1919 Investment Counsel, LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Biohaven Ltd (BHVN)?
As of 2025Q4, 573 institutions hold shares of Biohaven Ltd, with a combined market value of approximately 86.14M, accounting for 79.56% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -20.87%.
What is the biggest source of revenue for Biohaven Ltd?
In --, the -- business generated the highest revenue for Biohaven Ltd, amounting to -- and accounting for --% of total revenue.
